Reducing the Public Health Burden of Herpes Zoster and Postherpetic Neuralgia

Reducing the Public Health Burden of Herpes Zoster and Postherpetic Neuralgia

12 scary things your eyes say about your health. The study may be the first to look at a vaccination strategy to prevent expression of a disease caused by reactivation of a latent… VZV can reactive later in a person’s life and cause a painful, maculopapular rash called herpes zoster. It was an efficacy trial designed to determine whether a live, attenuated zoster vaccine could decrease the incidence and/or severity of herpes zoster and PHN. But the disease often causes telltale changes in the retina that can be … The author stressed that herpes zoster is not a benign disease. People with herpes zoster most commonly have a rash in one or two adjacent dermatomes (localized zoster).

Reducing the Public Health Burden of Herpes Zoster and Postherpetic Neuralgia
The primary outcome measure of the study was the burden of illness (BOI) of herpes zoster, a composite measure of incidence, severity, and duration of zoster-associated pain (ZAP); the secondary outcome measure of the study was incidence of PHN. After receiving their treatment, subjects were followed up for a minimum of 2 and an average of 3.1 years. The… Less commonly, the rash can be more widespread and affect three or more dermatomes. For at least 6 months following a diagnosis of herpes zoster, patients were asked to complete a brief pain inventory, a questionnaire to assess the severity of ZAP. Approximately 95% of the participants completed the study. It references a study by J.

The rash is usually painful, itchy or tingly. When stratified by age, BOI was reduced 65.5% in the 60- to 69-year-old group and by 55.4% in the 70-year-and-older group. There was also a 66.5% reduction in the incidence of PHN in all subjects, with comparable reductions in both age groups. Identifies nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. New vesicles continue to form over three to five days and progressively dry and crust over. Furthermore, in subjects in the vaccine group who did develop herpes zoster during the study period, the illness was less severe. In the United States, the mortality rate for vaccine-preventable diseases (or their complications) is as high as 70,000 people per year.[58] The US Centers for Disease Control and Prevention reported that persons 65 years and older are at greatest risk for vaccine-preventable diseases, including herpes zoster.[57,58] Although the mortality rate for herpes zoster is low, there is considerable preventable morbidity.

The “zoster” vaccine shows extraordinary promise for reducing the public health burden of herpes zoster and will likely be available in the near future. It is a persistent pain in the area where the rash once was.

You may also like

Reducing the Public Health Burden of Herpes Zoster and Postherpetic Neuralgia

Reducing the Public Health Burden of Herpes Zoster and Postherpetic Neuralgia

June 13, 2012 (Berlin, Germany) — Patients with inflammatory rheumatic diseases treated with tumor necrosis factor (TNF) inhibitors have up to a 75% increased risk for herpes zoster infection, compared with those treated with traditional disease-modifying antirheumatic drugs (DMARDs), researchers reported here at the European League Against Rheumatism Congress 2012. Furthermore, the epidemiology of herpes is shifting, and there is also a significant number of people who have genital herpes caused by infection with HSV-1. The risk for central nervous system (CNS) infection is already included in the labeling of natalizumab, but this research confirms the danger, first author Andrew J. Haman said, “In some cases it can get into the spinal fluid and cause inflammation around the brain and around the linings of the brain. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity.

Reducing the Public Health Burden of Herpes Zoster and Postherpetic Neuralgia
To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. Read the target audience, learning objectives, and author disclosures. There are no fees for participating in or receiving credit for this online educational activity. Study the educational content online or printed out. Vaccine and placebo recipients had similar rates of hospitalization or death during long-term follow-up. You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.

Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing “Edit Your Profile” at the top of your Medscape homepage. Up to 40 percent of babies born to mothers who are infected during the third trimester may acquire infection. Two patients died and 2 had neurologic sequelae. Each physician should claim only those credits that he/she actually spent in the activity. Should the mother acquire genital herpes during pregnancy, the risk increases to 40. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. Approval of this course for pharmacists is under a cosponsorship agreement between Medical Education Collaborative, Inc.

These activities will be marked as such and will provide links to the required software.

You may also like